| Literature DB >> 31097992 |
Toru Taniguchi1, Hiroaki Inagaki1, Daichi Baba2, Isao Yasumatsu3, Akiko Toyota1, Yasuyuki Kaneta1, Masaki Kiga1, Shin Iimura1, Takashi Odagiri1, Yoshihiro Shibata1, Kiyono Ueda4, Maki Seo4, Hiroki Shimizu4, Tomoki Imaoka1, Kiyoshi Nakayama2.
Abstract
To obtain a new anticancer drug, we focused on FER tyrosine kinase. Starting with high-throughput screening with our in-house chemical library, compound 1, which has a pyridine moiety, was found. Referring to their X-ray crystal structure with FES proto-oncogene tyrosine kinase, as a surrogate of FER followed by chemical modification including scaffold hopping of the pyridine template, we discovered pyrido-pyridazinone derivatives with potent FER kinase inhibitory activity. Here, we disclose the structure-activity relationship on the scaffold and representative compound 21 (DS21360717), which showed in vivo antitumor efficacy in a subcutaneous tumor model.Entities:
Year: 2019 PMID: 31097992 PMCID: PMC6511961 DOI: 10.1021/acsmedchemlett.8b00631
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345